A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer
Richard M. Lush(Moffitt Cancer Center), Anthony W. Tolcher(South Texas Accelerated Research Therapeutics), Marian Iwamoto(Merck & Co., Inc., Rahway, NJ, USA (United States)), K. Cerchio(Merck & Co., Inc., Rahway, NJ, USA (United States)), Kyriakos P. Papadopoulos(Texas Oncology), Michele Trucksis(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jacqueline B. McCrea(Merck & Co., Inc., Rahway, NJ, USA (United States)), Mark Stroh(CytomX Therapeutics (United States)), Amita Patnaik(South Texas Accelerated Research Therapeutics), Xiaodong Li(Merck & Co., Inc., Rahway, NJ, USA (United States)), Daniel M. Sullivan(Moffitt Cancer Center), Nancy Agrawal(Merck & Co., Inc., Rahway, NJ, USA (United States)), Keith Orford(Merck & Co., Inc., Rahway, NJ, USA (United States)), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), John A. Wagner(Merck & Co., Inc., Rahway, NJ, USA (United States)), Diana Selverian(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 2
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k